Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Clinical Trials Coronavirus COVID-19 Vaccines

UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials

Vaccine Frontrunner Is Benefiting From Public-Private Collaboration

  • News

Executive Summary

The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.

You may also be interested in...



Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial

Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.

Argenx’s Autoimmune Disease Blockbuster-In-Waiting Gets FDA Decision Date

The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.

Sofinnova Raises €445m To Help European Biotechs Reach Critical Mass - And SPACs Are A Welcome Innovation

VC’s new fundraising is oversubscribed, reflecting growing confidence in developing European biotech sector.

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Coronavirus COVID-19 Vaccines
UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By